Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment

Zhu, Chaojie; Ji, Zhiheng; Ma, Junkai; Ding, Zhijie; Shen, Jie; Wang, Qiwen

doi:10.3390/pharmaceutics13070940

Cited by 21 publications

(9 citation statements)

References 94 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When IBU-SNE-FM contacts body fluids, various components of SNEDDS will self-assemble into lamellar liquid crystals due to hydrogen bonding and hydrophobic forces, and further spontaneously form nanoemulsions (NE), which can facilitate the transdermal penetration of the drug ( Figure 9 ). In vitro permeation experiments of rat skin showed that the drug permeability coefficient of IBU-SNE-FM was 1.79 and 1.67 times higher than that of IBU’s phosphate buffer, and the IBM nanofibers (IBU was directly dissolved in PLLA ethanol solution for electrospinning) after 4 h. In the acute inflammation model in rats induced with CFA, the IBU-SNE-FM group significantly reduced the inflammation infiltration and the swelling thickness of rat paws, which can effectively exert the anti-inflammatory effect (Xiang et al., 2019 ).…”

Section: Ra Transdermal Dosage Formmentioning

confidence: 99%

See 1 more Smart Citation

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

Rheumatoid arthritis is a chronic autoimmune disease, with the features of recurrent chronic inflammation of synovial tissue, destruction of cartilage, and bone erosion, which further affects joints tissue, organs, and systems, and eventually leads to irreversible joint deformities and body dysfunction. Therapeutic drugs for rheumatoid arthritis mainly reduce inflammation through regulating inflammatory factors. Transdermal administration is gradually being applied to the treatment of rheumatoid arthritis, which can allow the drug to overcome the skin stratum corneum barrier, reduce gastrointestinal side effects, and avoid the first-pass effect, thus improving bioavailability and relieving inflammation. This paper reviewed the latest research progress of transdermal drug delivery in the treatment of rheumatoid arthritis, and discussed in detail the dosage forms such as gel (microemulsion gel, nanoemulsion gel, nanomicelle gel, sanaplastic nano-vesiclegel, ethosomal gel, transfersomal gel, nanoparticles gel), patch, drug microneedles, nanostructured lipid carrier, transfersomes, lyotropic liquid crystal, and drug loaded electrospinning nanofibers, which provide inspiration for the rich dosage forms of transdermal drug delivery systems for rheumatoid arthritis.

show abstract

Section: Ra Transdermal Dosage Formmentioning

confidence: 99%

Section: Ra Transdermal Dosage Formmentioning

confidence: 99%

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Among them, nanomedicine has achieved tremendous progress in cancer management [12][13][14]. Nanoparticles can protect the cargo from degradation and facilitate their accumulation at tumor sites through passive diffusion or active targeting, optimizing the drug biodistribution [15][16][17][18][19]. Especially in the past few years, nanocarriers that can respond to biological cues in the tumor microenvironment (TME) attracted increasing attention [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Recent advances of bioresponsive polymeric nanomedicine for cancer therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

A bioresponsive polymeric nanocarrier for drug delivery is able to alter its physical and physicochemical properties in response to a variety of biological signals and pathological changes, and can exert its therapeutic efficacy within a confined space. These nanosystems can optimize the biodistribution and subcellular location of therapeutics by exploiting the differences in biochemical properties between tumors and normal tissues. Moreover, bioresponsive polymer-based nanosystems could be rationally designed as precision therapeutic platforms by optimizing the combination of responsive elements and therapeutic components according to the patient-specific disease type and stage. In this review, recent advances in smart bioresponsive polymeric nanosystems for cancer chemotherapy and immunotherapy will be summarized. We mainly discuss three categories, including acidity-sensitive, redox-responsive, and enzyme-triggered polymeric nanosystems. The important issues regarding clinical translation such as reproducibility, manufacture, and probable toxicity, are also commented.

show abstract

“…In particular, the inherent tropism of bacteria for different types of tumors and their ability to overcome the vascular barrier means that they have potential for use in tumor-targeting delivery ( Wu et al, 2021 ). Furthermore, the cell surfaces of bacteria can be decorated with organic or inorganic materials, including various types of nanomaterial and therapeutic agents for cargo delivery ( Zhu C. et al, 2021 ; Ye et al, 2021 ; Jiménez-Jiménez et al, 2022 ). Additionally, bacterial derivatives—including outer membrane vesicles (OMVs), minicells, and bacterial protoplast-derived nanovesicles—have been shown to have great potential as safe and efficient drug carriers ( Ali et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Recent advances in bacteria-mediated cancer therapy

Liang

Wang

Shao

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is among the leading cause of deaths worldwide. Although conventional therapies have been applied in the fight against the cancer, the poor oxygen, low extracellular pH, and high interstitial fluid pressure of the tumor microenvironment mean that these treatments fail to completely eradicate cancer cells. Recently, bacteria have increasingly been considered to be a promising platform for cancer therapy thanks to their many unique properties, such as specific tumor-targeting ability, high motility, immunogenicity, and their use as gene or drug carriers. Several types of bacteria have already been used for solid and metastatic tumor therapies, with promising results. With the development of synthetic biology, engineered bacteria have been endowed with the controllable expression of therapeutic proteins. Meanwhile, nanomaterials have been widely used to modify bacteria for targeted drug delivery, photothermal therapy, magnetothermal therapy, and photodynamic therapy, while promoting the antitumor efficiency of synergistic cancer therapies. This review will provide a brief introduction to the foundation of bacterial biotherapy. We begin by summarizing the recent advances in the use of many different types of bacteria in multiple targeted tumor therapies. We will then discuss the future prospects of bacteria-mediated cancer therapies.

show abstract

Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment

Cited by 21 publications

References 94 publications

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

Recent advances of bioresponsive polymeric nanomedicine for cancer therapy

Recent advances in bacteria-mediated cancer therapy

Contact Info

Product

Resources

About